



Formulation and evaluation of SMEDDS containing ezetimibe by employing coconut oil as oil and tween 80, peg 400 as surfactant system

P Tripura Sundari^{1*}, P Mounika²

¹ Associate Professor, RBVRR Women's College of Pharmacy, Hyderabad, Telangana, India

² RBVRR Women's College of Pharmacy, Hyderabad, Telangana, India

Abstract

Solubility is the important process for most of the drug to solubilize in a given solvent to give homogenous solution. The greater the solubility of drug, the greater will be the systemic dissolution showing desired pharmacological response. New techniques have been developed to improve the solubility rate of poorly soluble drugs. Solid dispersion, Complexation, Particle size reduction, co-solvency, etc.

Among which, a recent approach lipid base formulations (SMEDDS) are attracting the formulation scientists. These lipid based formulations include SMEDDS, SNEDDS. SMEDDS are nothing but the emulsion containing oil, surfactant, co-surfactant and drug which form oil in water emulsion upon mild agitation with aqueous phase. In the present study SMEDDS containing Ezetimibe, a BCS class II drug is formulated. As Ezetimibe is insoluble in water, lipid based formulations SMEDDS are developed by employing Coconut as lipid phase, Tween 80, PEG400 were selected as surfactant mixture. The better formulations were selected based on the evaluation parameters like drug content, %transmittance, drug release studies.

Keywords: SMEDDS (self-micro emulsifying drug delivery system), ezetimibe, PEG 400, tween 80, ternary diagram

Introduction

Oral drug delivery is the most common route used to deliver drugs. Drugs which are highly soluble/hydrophilic can be easily delivered by oral route which increase the bioavailability of drug in body. Drugs which are lipophilic offer least advantage because of their low aqueous [1-4] solubility. Various solubility enhancement techniques like solid dispersion, complexation, salt formation of drug, co-solvency, use of surfactants etc., are employed to improve the solubility and bioavailability of poorly aqueous soluble drugs. Each of this technique provides some disadvantages.

Oral delivery of poorly water soluble drugs using lipid as vehicle is a new and recent approach. Lipid based formulations are such as liposome, solid lipid nanoparticle, self-emulsifying administration of lipids along with lipophilic drugs offer better advantages by increasing the bioavailability of drugs and prolongs the GI residence time of drug.

Among the various lipid based formulation self-emulsifying formulations are receiving greater attention by formulation scientist as they are effect in hydrophobic drug delivery, increased stability, self-dispersing nature, ease of scale up [5-8]. These systems are developed by using a lipid carrier which improves the gastro intestinal absorption of poorly water soluble drugs, allows the drug to remain in dissolved state by protecting the drug from enzymatic reaction, thermodynamically stable, easily manufactured and suitable for oral drug delivery. Compounds used in this system include oil, surfactant, and co-surfactant.

The function of oil in this system is to solubilize the lipophilic drug in order to improve the drug loading and bioavailability. Medium chain triglycerides are most commonly used [9-14] as

they are resistant to precipitation. Hydrophobic drugs are easily solubilized in oil. As solubility is limited in oils, micro emulsification of oil and surfactant is employed which enhances the drug solubility in oils. Enhancement of drug solubility primarily depends on factors such as efficiency and rapidity to micro emulsify the selected oil, solubility of drug in surfactant. Nonionic surfactants are commonly preferred in formulation as they have less CMC value, they are less toxic, provides a greater emulsion stability over a wide range of pH and ionic strength. Concentration of co-surfactant plays a major role in lipid based formulation. Selection of surfactant and co-surfactant is necessary for the solubilization of drug. Organic solvents such as ethanol, propylene glycol, polyethylene glycol are suitable for oral drug delivery.

Materials and Method

Materials

Ezetimibe is obtained as gift sample from Sun pharma, Coconut oil, Tween 80, PEG 400, MCC pH 102, and all other ingredients used are of pharmacoepial standards.

Solubility study

The solubility of Ezetimibe is checked in various compounds like oil, surfactants, and co-surfactants respectively. Excess amount of drug was added in each test tube containing 5ml of solvent, the test tubes were placed in orbital shaker for 48hrs to achieve solubility equilibrium. The supernatant was separated and filtered through a membrane filter to remove the undissolved drug. Solubility of Ezetimibe was determined by analyzing the filtrate at 315nm.

Construction of ternary phase diagram

Phase behavior of each SMEDDS is studied carefully by using the phase diagram. It is one of the important characteristics of SMEDDS to show the changes when the system is diluted, which may cause drug precipitation. Therefore, phase behavior of each SMEDDS should be carefully studied. Based on solubility shown by drug in different ratios of surfactants the ternary diagrams were developed.

Formulation of SMEDDS of Ezetimibe

Based on ternary diagrams, a series of formulations were prepared by using different ratios of oil: S_{mix} . The formulations were stored at room temperature until further use.

Table 1: Different formulations prepared with different ratios of oil: S_{mix}

Formulation No	S_{mix} (Tween80 : PEG 400)	Oil : S_{mix}
C1	1:1	1:1
C2		1:2
C3		1:3
C4		2:1
C5		3:1
C6	1:2	1:1
C7		1:2
C8		1:3
C9		2:1
C10		3:1
C11	1:3	1:1
C12		1:2
C13		1:3
C14		2:1
C15		3:1
C16	2:1	1:1
C17		1:2
C18		1:3
C19		2:1
C20		3:1

Characterization

Characterization of SMEDDS

SMEDDS pre-concentrate equivalent to dose of drug was diluted with distilled water. This micro emulsion was taken for in vitro characterization.

Appearance

Appearance of all the formulation SMEDDS (C1-C20) was tested visually against white and black background.

Conductance

The electro conductance of resultant micro emulsion system was measured by using conductivity meter (CM 180, ELICO). Each measurement was carried out in triplicate.

% Transmittance

The percentage transmittances of samples (C1-C20) are measured by using colorimeter (CL 223 colorimeter, ELICO)

Emulsification of samples

To assess emulsification properties of prepared formulations (C1-C20) each formulation was introduced into a 250ml glass

beaker containing distilled water at room temperature and contents were agitated gently. The tendency to form clear or transparency emulsion is considered as good, when the formation was poor or milky in appearance then it is considered as bad emulsion.

Stability studies

The stability of lipid based formulation is essential for its performance, which can be adversely effected by the precipitation of drug. In addition formulations having poor stability leads to phase separation affecting the formulation performance and visual appearance. Stability studies of formulations are performed by heat cooling, centrifugation, and freeze thaw cycle.

1. Heat cooling cycle: Six cycles were carried out between 40°C to 45°C. In between these temperatures, formulations were stored not less than 48hrs. The formulations which are stable at these temperatures are subjected to centrifugation.
2. Centrifugation: The formulations which passed through above test are centrifuged at 3500rpm for 30min. The formulations that did not show phase separation were taken for freeze thaw test.
3. Freeze thaw cycle: Freeze thaw cycles were carried out between -20°C to +25°C. Formulations are stored at each temperature not less than 48hrs.

Droplet size analysis

The droplet size of emulsions were determined by using zetasizer which is able to measure sizes between 10 and 500 nm. Light scattering is monitored at 25°C at a 90° angle, after external standardization with spherical polystyrene beads. The nanometric size range of the particle is retained even after 100 times dilution with water which proves the systems compatibility with excess water.

Zeta potential

The charge of the oil droplets in conventional SMEDDS is negative due to presence of free fatty acids. The zeta potential values were determined by using Zetasizer.

Preparation of solid SMEDDS

The prepared SMEDDS are converted into solid dosage forms by adding excipients like MCC pH 102 the resultant mixture is weighed and filled in hard gelatin capsule. These are stored for further analysis.

Drug content

The formulated SMEDDS equivalent to 10mg of drug is taken and dissolved in methanol and the resultant sample with proper dilutions are checked for their absorbance in UV (UV-2203, Systronics) at 232 nm and percent drug content is calculated.

Uniformity weight of capsule

Fill the capsule shell with formulation (C1-C20). Weight of individual capsule should be noted and average weight was calculated. Not more than two individual weight deviate from average weight.

In vitro dissolution rate study

In vitro dissolution rate study of all the prepared formulations (C1-C20) containing 40mg of dug Ezetimibe was performed by using USP dissolution apparatus I (basket) (USP TDL-14L dissolution tester, electro lab). Acetate buffer of pH 4.5 was used as dissolution media maintained at 37°C and 75rpm. 5ml of aliquots were withdrawn at specific time intervals and the same amount of fresh buffer was replaced to maintain sink conditions. The collected aliquots were analyzed for drug content at 232nm using UV-Visible spectrophotometer (UV-2203, Systronics). The test was performed in triplicate. The prepared formulations (C1-C20) were compared with the marketed product (Ezedoc® 10) of Ezetimibe, with respect to drug release.

Results and Discussion

Solubility study

The solubility studies of Ezetimibe in different compounds

Table 2: Solubility of drug in different surfactant

S. No	Solvent	Amount of drug dissolved (gm)
1	Ethanol	2
2	PEG 400	2.5
3	Propylene glycol	1
4	Tween 80	3
5	Coconut oil	1.5
6	Coconut oil	1
7	Soybean oil	0.5




Fig 1: Solubility profile of Ezetimibe in various solvents Solubility study of Ezetimibe in various compounds

The solubility of drug was checked in various compounds and the values ranges from 23-48mg/ml. Based on solubility studies coconut oil was selected as oil phase. Tween 80 PEG 400 and labrasol selected as surfactant and co-surfactant further the ratios of surfactant: co-surfactant was fixed from solubility data obtained from the studies of different ratios of surfactant: co-surfactant.

Table 3: Solubility of drug in different ratios of surfactant and co-surfactant(S mix)

S. No	S: Co S(S _{mix})	Amount of drug dissolved (mg)
1	1:1	300
2	1:2	500
3	3:1	200
4	4:1	120
5	5:1	100
6	1:3	450
7	1:2	350

From the above study 1:1, 1:2, 1:3 and 2:1 were selected further for formulation of SMEDDS




Fig 2: solubility profile of drug in different S_{mix} ratio

The solubility studies of Ezetimibe in different ratios of S_{mix} were carried out and it was clear from the studies that 1:1, 1:2, 1:3 and 2:1 ratio of S_{mix} has shown better solubility of drug when compared to other ratios.

Construction of ternary phase diagram

Oil, water and S_{mix} were taken as each apex of ternary graph

and ternary diagrams were constructed separately for each group to identify the micro emulsion region.




Fig 3(a): Ternary phase diagram of 1:1 ratio of Coconut oil: S_{mix} (Tween 80: PEG 400) and water




Fig 3(b): Ternary phase diagram of 1:2 ratio of Coconut oil: S_{mix} (Tween 80:PEG400) and water




Fig 3(c): Ternary phase diagram of 1:3 ratio of Coconut oil: S_{mix} (Tween 80:PEG400) and water




Fig 3(d): Ternary phase diagram of 2:1 ratio of Coconut oil: S_{mix} (Tween 80:PEG400) and water

From the above ternary diagrams, we can select the better emulsification zone for each ratio of S mix without getting the drug precipitated out of each system.

Characterization of SMEDDS

Appearance

At the end of 24 hrs the emulsions were visually inspected for clarity, phase separation and precipitation of drug.

Table 4: Assessment of physical compatibility by visual observation of prepared formulation

S No	Formulation	After 24 hours		
		Phase separation	Precipitation	Clarity
1	C1	No	No	Not clear
2	C2	No	No	Slightly less clear
3	C3	No	No	Clear
4	C4	No	No	Dull
5	C5	No	No	Dull
6	C6	No	No	Greyish white
7	C7	No	No	Not Clear
8	C8	No	No	Clear
9	C9	No	No	Dull
10	C10	No	No	Dull
11	C11	No	No	Not clear
12	C12	No	No	Less clear
13	C13	No	No	Clear

14	C14	No	No	Dull
15	C15	No	No	Dull
16	C16	No	No	Greyish white
17	C17	No	No	Slightly less clear
18	C18	No	No	Clear
19	C19	No	No	Dull
20	C20	No	No	Dull

C3, C8, C13 and C18 were observed to be clear after 24 hrs. Whereas other formulations were either cloudy or opaque in physical appearance.

Conductance

Presence of oil in water emulsion formulation was confirmed by measuring conductivity. All SMEDDS are water continuous emulsion systems, some decrease in conductance were due to presence of oil droplets showing resistance to conductance and so decrease in conductance was observed.

Table 5: Electro conductivity of SMEDDS containing Ezetimibe

S No	formulation	Conductance		
		I	II	III
1	C1	46	46.3	46
2	C2	47.7	47.2	47.5
3	C3	48.1	47.9	47.6
4	C4	44.6	45.1	44.9
5	C5	44.2	44.2	44.3
6	C6	45.4	45.6	45.3
7	C7	46.5	46.7	46.3
8	C8	48.4	48.4	48.4
9	C9	45.2	45.1	45
10	C10	44.2	44	44.1
11	C11	46.1	46.8	46.9
12	C12	47.5	47.8	47.9
13	C13	48.9	48.8	48.8
14	C14	45.5	45.6	45.1
15	C15	42.3	42.1	42.9
16	C16	47.3	47.3	47.3
17	C17	48.1	48.1	48.3
18	C18	49.2	49.4	49.2
19	C19	45.8	46.1	45.9
20	C20	42.3	42.6	42.4

The conductance values for all prepared formulations were ranging from (C1-C20) 40-50, among which among which C3, C8, C13 and C18 were showing higher values of conductance.

Table 7: Drug content values of prepared formulations

S. No	Formulation	% Drug content		
		I	II	III
1	C1	85.2	84	84.6
2	C2	87.5	86	86.7
3	C3	98.2	98	98.2
4	C4	92.1	92.8	92.3
5	C5	84.2	85.1	84.6
6	C6	87.5	87.5	87.9
7	C7	87.1	87	87.3
8	C8	98.9	98.7	98.7
9	C9	90.6	90.5	90.2
10	C10	89.5	89.4	89.1
11	C11	88.5	88.7	88.2

Percentage transmittance

The clarity of micro emulsions was checked by transparency in terms of percentage transmittance (%T).

Table 6: Transmittance of SMEDDS containing Ezetimibe

S. No	Formulation	Transmittance (%T)		
		I	II	III
1	C1	64	65	64
2	C2	75	74	72
3	C3	81	82	82
4	C4	48	48	48
5	C5	44	44	41
6	C6	62	60	64
7	C7	71	71	70
8	C8	87	87	86
9	C9	46	47	44
10	C10	39	40	42
11	C11	59	60	59
12	C12	69	68	69
13	C13	88	87	88
14	C14	51	50	54
15	C15	49	47	49
16	C16	77	78	74
17	C17	81	84	82
18	C18	98	98	98
19	C19	59	58	58
20	C20	47	45	46

In the present study the transmittance for all the formulations ranging from (C1-C20) 30-98 and the formulations C3, C8, C13 and C18 were showing higher values.

Characteristics of solid SMEDDS

Drug content

The drug content of Ezetimibe SMEDDS formulation was measured by using UV-Visible spectroscopic method. (UV-2203, Systronics)

12	C12	84.2	84.5	84.2
13	C13	98.7	99	98.8
14	C14	92.5	92.8	92.1
15	C15	89.5	90.1	89.6
16	C16	86.2	86.4	86.1
17	C17	88.5	88.9	88.4
18	C18	98.7	98.5	98.9
19	C19	87.5	87.1	87.9
20	C20	86.2	86.5	86.7

The drug content values for all prepared formulations were ranging from (C1-C20) 92-99, among which C3, C8, C13, C18 showing high drug content.

Uniformity of weight of capsule

Uniformity weight of capsule was determined for all formulations. The value of average weight of capsule range from 525.7-527.5mg. The weight variation was observed within acceptable limit i.e., less than $\pm 7.5\%$ capsule as per IP 2007.

In vitro dissolution studies

In vitro dissolution studies have been performed on all formulations (C1-C20) and drug release is observed. Among all C3, C8, C13 and C18 had shown increased drug release when compared with other formulations.




Fig 4(a): Dissolution profile of all the prepared SMEDDS (C1-C5) containing Ezetimibe




Fig 4(b): Dissolution profile of all the prepared SMEDDS (C6-C10) containing Ezetimibe




Fig 4(c): Dissolution profile of all the prepared SMEDDS (C11-C15) containing Ezetimibe




Fig 4(d): Dissolution profile of all the prepared SMEDDS (C16-C20) containing Ezetimibe

The formulation batches C3, C8, C13 and C18 are compared with that of marketed product (Ezedoc®10) and pure drug (Ezetimibe 10 mg) with respect to drug dissolution profile




Fig 5: Comparison of finalized formulations with marketed preparation and pure drug

The formulations C3, C8, C13 and C18 were compared with marketed preparation (Ezedoc[®]10) and pure drug. The prepared formulations had shown very high dissolution studies than the marketed product and pure drug.

C3, C8, C13 and C18 are found as optimized formulations containing Ezetimibe and further studies are carried out on these formulations.

Zeta potential

Zeta potential was performed for all the formulations to determine the potential stability of colloidal systems. Zeta

potential was determined by MALVERN zeta sizer instruments and was monitored at 25° c at a scattering angle 90°.

Table 8: Zeta potential of SMEDDS containing Ezetimibe

S. No	Formulation	Zeta potential (mV)
1	C3	-14.5
2	C8	-18.5
3	C13	-16.5
4	C18	-19.5




Fig 6

SMEDDS formulation consist of non-ionic components which show relatively neutral charge it means it will not affected by body membrane charge during absorption. Zeta potential performed on all finalized formulations the values are found to be (-14.5mV, -18.5mV, -16.5mV, -19.5mV). The droplet size of emulsions which could be determined by a photon correlation spectroscopy using a zetasizer which able to measure sizes between 10 and 500 nm.

Table 9: Particle size of SMEDDS containing Ezetimibe

S. No	Formulation	Z-Average (nm)
1	C3	557.1
2	C8	522.5
3	C13	376.7
4	C18	352.5




Fig 7(a): Particle size of SMEDDS (C3) containing Ezetimibe




Fig 7(b): Particle size of SMEDDS (C8) containing Ezetimibe




Fig 7(c): Particle size of SMEDDS (C13) containing Ezetimibe




Fig 7(d): Particle size of SMEDDS (C18) containing Ezetimibe

Stability studies

Stability studies of the formulations are tabulated below. C18 had shown better stability when compared with other formulations

Table 10: Stability studies of SMEDDS

S. No	Formulations	Solubility Studies	
		Precipitation	Phase separation
1	C3	Yes	Yes
2	C8	Yes	Yes
3	C13	Yes	Yes
4	C18	No	No

Conclusion

In this study, the SMEDDS of Ezetimibe were prepared using Coconut oil, Tween 80, PEG 400. Based on ternary phase diagrams Tween 80 and PEG400 were selected as surfactant, co-surfactant respectively. The ratios of surfactant, co-surfactant was fixed based on solubility studies. Among all the prepared formulations C3, C8, C13 and C18 were showing

better drug content values, %transmittance and conductivity values, further the drug release values also proved that among all the formulations C3, C8, C13 and C18 are showing better profile, these formulations were compared with marketed formulation with respect to drug release data. Hence from all the studies carried out SMEDDS of Ezetimibe can be successfully prepared by using Coconut oil, S_{mix}(Tween 80: PEG 400) to improve its solubility profile.

References

1. Advait R Dixit, Sadhana J Rajput. Preparation and bioavailability assessment of SMEDDS containing valsartan AAPS Pharm Sci. Tech. 2010; 11(1):314-21.
2. Chaudhary A, Nagaich U, Gulati N, Sharma V, Khosa R. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review. J Adv. Pharm. Edu. Res. 2012; 2(1):32-67.
3. Kang J, Dong H, Chul Y, Han G. Effects of solid carriers on the crystalline properties, dissolution and

- bioavailability of flurbiprofen in solid self nano emulsifying drug delivery system (solid SNEDDS).” *Eur. J Pharm. Biopharm.* 2012; 80:289-297.
4. Kumar S, Gupta S, Sharma P. Self-emulsifying drug delivery systems for oral delivery of lipid based formulations - A review. *African J Bas. Appl. Sci.* 2012; 4(1).
 5. Kalhapure R, Krishnacharya G, Kamanchi A. Oleic acid based heterolipid synthesis, characterization and application in self-microemulsifying drug delivery system. *Int. J Pharm.* 2012; 425:9-18.
 6. Mittal P, Rana AC, Bala R, Seth N. Lipid based self microemulsifying drug delivery system (smedds) for lipophilic drugs: an acquainted review. *Int Res J of pharm.* 2011; 2(12).
 7. Mistry R, Sheth N. A review: Self emulsifying drug delivery system.” *Int.J.Pharm. Pharm. Sci.* 2011; 3(2):23-28.
 8. Nekkanti V, Karatgi P, Prabhu R, Pillai. Solid self-microemulsifying formulation for Candesartan Cilexetil. *AAPS Pharm. Sci. Tech.* 2010; 11(1):9-17.
 9. Pouton CW. Lipid formulations for oral administration of drugs Nonemulsifying, self emulsifying and self-micro emulsifying drug delivery systems. *Eur. J Pharm. Sci.* 2000; (11):93-98.
 10. Patil RV, Patil KK, Mahajan VR, Dhake AS. Self emulsifying therapeutic-a review. *Int. J of pharma. Bio Archives.* 2012; 3(3):481-486.
 11. Kim CK, Ryun SA, Park KM, Lim SJ, Hwang SJ, *Int. J Pharmaceutics.* 1997; 147:131-4.
 12. Khoo SH, Humber Stone AJ, Porter CJH, Edwards GA, Charman WN. *Int. J Pharmaceutics.* 1998; 167:155-164.
 13. Kim HJ, Yoon KA, Hahn M, Park ES, Chi SC. *Drug Dev and Ind Pharm.* 2000; 26(5):523-5224.